| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
REGN Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.
Regeneron Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$553.24 |
| 52 Week High | US$441.00 |
| 52 Week Low | US$686.62 |
| Beta | 0.21 |
| 1 Month Change | -15.30% |
| 3 Month Change | -5.14% |
| 1 Year Change | -7.75% |
| 3 Year Change | 41.92% |
| 5 Year Change | 52.19% |
| Change since IPO | 2,518.89% |
Recent News & Updates
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Safely
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Regeneron Pharmaceuticals: Undervalued Cash Generating Machine
REGN has a strong economic moat protected by technology and patents. Profitability and strength of balance sheet are well above industry average. Market is overestimating the impact of tapering sales of their COVID treatment and potential biosimilars to Eylea. Current stock price offers 60-140% upside.
Shareholder Returns
| REGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.6% | 1.0% | 2.0% |
| 1Y | -7.8% | 12.5% | 27.6% |
Return vs Industry: REGN underperformed the US Biotechs industry which returned 12.4% over the past year.
Return vs Market: REGN underperformed the US Market which returned 27.6% over the past year.
Price Volatility
| REGN volatility | |
|---|---|
| REGN Beta | 0.21 |
| Industry Beta | 0.98 |
| Market Beta | 1 |
Stable Share Price: REGN is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: REGN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 9,635 | Leonard Schleifer | https://www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals Fundamentals Summary
| REGN fundamental statistics | |
|---|---|
| Market Cap | US$57.52b |
| Earnings (TTM) | US$6.21b |
| Revenue (TTM) | US$12.20b |
9.3x
P/E Ratio4.7x
P/S RatioIs REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REGN income statement (TTM) | |
|---|---|
| Revenue | US$12.20b |
| Cost of Revenue | US$4.52b |
| Gross Profit | US$7.68b |
| Expenses | US$1.48b |
| Earnings | US$6.21b |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 04, 2021
| Earnings per share (EPS) | 59.69 |
| Gross Margin | 62.98% |
| Net Profit Margin | 50.87% |
| Debt/Equity Ratio | 13.1% |
How did REGN perform over the long term?
See historical performance and comparisonValuation
Is Regeneron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
38.0%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: REGN ($553.24) is trading below our estimate of fair value ($891.75)
Significantly Below Fair Value: REGN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: REGN is good value based on its PE Ratio (9.3x) compared to the US Biotechs industry average (23.6x).
PE vs Market: REGN is good value based on its PE Ratio (9.3x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: REGN's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: REGN is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (2.9x).
Future Growth
How is Regeneron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
-6.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: REGN's earnings are forecast to decline over the next 3 years (-6.6% per year).
Earnings vs Market: REGN's earnings are forecast to decline over the next 3 years (-6.6% per year).
High Growth Earnings: REGN's earnings are forecast to decline over the next 3 years.
Revenue vs Market: REGN's revenue is expected to decline over the next 3 years (-1.9% per year).
High Growth Revenue: REGN's revenue is forecast to decline over the next 3 years (-1.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: REGN's Return on Equity is forecast to be high in 3 years time (20.8%)
Past Performance
How has Regeneron Pharmaceuticals performed over the past 5 years?
34.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: REGN has a high level of non-cash earnings.
Growing Profit Margin: REGN's current net profit margins (50.9%) are higher than last year (40.4%).
Past Earnings Growth Analysis
Earnings Trend: REGN's earnings have grown significantly by 34.6% per year over the past 5 years.
Accelerating Growth: REGN's earnings growth over the past year (108%) exceeds its 5-year average (34.6% per year).
Earnings vs Industry: REGN earnings growth over the past year (108%) exceeded the Biotechs industry 4.9%.
Return on Equity
High ROE: REGN's Return on Equity (41%) is considered outstanding.
Financial Health
How is Regeneron Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: REGN's short term assets ($13.3B) exceed its short term liabilities ($3.7B).
Long Term Liabilities: REGN's short term assets ($13.3B) exceed its long term liabilities ($2.6B).
Debt to Equity History and Analysis
Debt Level: REGN's debt to equity ratio (13.1%) is considered satisfactory.
Reducing Debt: REGN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: REGN's debt is well covered by operating cash flow (114.8%).
Interest Coverage: REGN's interest payments on its debt are well covered by EBIT (91.3x coverage).
Balance Sheet
Dividend
What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate REGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate REGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if REGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if REGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of REGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
Leonard Schleifer (68 yo)
33.75yrs
Tenure
US$135,350,121
Compensation
Dr. Leonard S. Schleifer, M.D., Ph D., founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron P...
CEO Compensation Analysis
Compensation vs Market: Leonard's total compensation ($USD135.35M) is above average for companies of similar size in the US market ($USD11.20M).
Compensation vs Earnings: Leonard's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: REGN's management team is considered experienced (2.5 years average tenure).
Board Members
Experienced Board: REGN's board of directors are seasoned and experienced ( 19.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: REGN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Regeneron Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Regeneron Pharmaceuticals, Inc.
- Ticker: REGN
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$57.519b
- Shares outstanding: 103.97m
- Website: https://www.regeneron.com
Number of Employees
Location
- Regeneron Pharmaceuticals, Inc.
- 777 Old Saw Mill River Road
- Tarrytown
- New York
- 10591-6707
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/16 22:25 |
| End of Day Share Price | 2021/10/15 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.